Clinical trials continue to shape metastatic breast cancer treatment, making therapies safer, more tolerable, and more ...

Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...

Initial support came from in-person groups and survivor stories, providing essential emotional connections and shared experiences. The pandemic shifted support to virtual platforms, which lacked the ...

“Full House” star Dave Coulier, now undergoing treatment for tongue cancer, sat down for an interview with CURE.

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Common symptoms that palliative care teams see in patients with metastatic breast cancer include pain, menopausal symptoms, ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

Integrative oncology combines standard cancer treatments with complementary therapies to manage symptoms and improve ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

Grieving an online friend can feel illegitimate due to the absence of conventional mourning rituals, yet the grief is genuine and valid. Losing an online friend to cancer reminded me that grief is ...

Although great strides have been made in research for breast cancer vaccines, such a vaccine is likely years away from ...

The landscape of breast cancer research is undergoing a significant shift, moving toward complex, combination strategies designed to overcome the body’s own immune suppression.